J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal Article
High-dose chemotherapy and autologous transplant with peripheral-blood stem cells.
TL;DR: This type of hematopoietic rescue following high-dose chemotherapy has now been used in a number of studies for the treatment of a variety of malignancies and various mobilization and cell selection techniques are currently being evaluated for further refinement of this technique.
Journal ArticleDOI
The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B‐cell lymphoma
Zdravko Mitrović,Zdravko Mitrović,Martin Bast,Philip J. Bierman,Robert G. Bociek,Julie M. Vose,Wing C. Chan,James O. Armitage +7 more
TL;DR: The addition of rituximab to chemotherapy significantly decreases the frequency of CNS relapses in DLBCL patients treated prior to and during the ritUXimab era.
Journal ArticleDOI
Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
Alex F. Herrera,Nancy L. Bartlett,Radhakrishnan Ramchandren,Julie M. Vose,Alison J. Moskowitz,Tatyana Feldman,Ann S. LaCasce,Stephen M. Ansell,Craig H. Moskowitz,Keenan Fenton,Kazunobu Kato,Abraham P. Fong,Ranjana H. Advani +12 more
TL;DR: A phase 1/2 study is ongoing to evaluate the safety and antitumor activity of BV administered in combination with nivolumab as first salvage therapy in patients with R/R classical HL after standard frontline chemotherapy.
Journal ArticleDOI
Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-κB and mTOR Dual-Targeting Approach
Nagendra K. Chaturvedi,Rajkumar N. Rajule,Ashima Shukla,Prakash Radhakrishnan,Gordon L. Todd,Amarnath Natarajan,Julie M. Vose,Shantaram S. Joshi +7 more
TL;DR: Results suggest that 13-197 as a single agent disrupts the NF-κB and mTOR pathways leading to suppression of proliferation and increased apoptosis in malignant MCL cells including reduction in tumor burden in mice.
Posted ContentDOI
Pathognomonic and epistatic genetic alterations in B-cell non-Hodgkin lymphoma
Man Chun John Ma,Saber Tadros,Alyssa Bouska,Tayla Heavican,Haopeng Yang,Qing Deng,Dalia Moore,Ariz Akhter,Keenan Hartert,Neeraj Jain,Jordan Showell,Sreejoyee Ghosh,Lesley Street,Marta Davidson,Christopher D. Carey,Joshua W.D. Tobin,Deepak Perumal,Julie M. Vose,Matthew A. Lunning,Aliyah R. Sohani,Benjamin J. Chen,Shannon M. Buckley,Loretta J. Nastoupil,R. Eric Davis,Jason R. Westin,Nathan Fowler,Samir Parekh,Maher K. Gandhi,Sattva S. Neelapu,Douglas A. Stewart,Javeed Iqbal,Timothy C. Greiner,Scott J. Rodig,Adnan Mansoor,Michael R. Green +34 more
TL;DR: The first cross-sectional analysis of mutations and DNA copy number alterations across major B-NHL subtypes and a framework of co-occurring genetic alterations that deregulate genetic hallmarks and likely cooperate in lymphomagenesis are provided.